Magic Health’s flagship ingredient, PERFQUQ™ (Pyrroloquinoline Quinone Disodium Salt), has officially earned Self-GRAS (Generally Recognized as Safe) status in the United States following unanimous approval from an independent expert panel. This key regulatory milestone confirms the ingredient's safety for use in U.S. foods and beverages, marking a significant step forward in Magic Health’s international expansion. CIRS Group provided end-to-end support throughout the GRAS assessment.

The U.S. FDA proposes making the voluntary Generally Recognized as Safe (GRAS) notification mandatory while preserving "Self-GRAS" statutory status. If finalized, companies face mandatory filing timelines: a one-year window to submit abbreviated notices for existing unnotified ingredients, exemptions for current "no questions" letters, and required pre-market FDA submissions for new ingredients.

On October 19, 2026, the FDA simultaneously issued two NDI guidance documents to further refine the requirements for submitting New Dietary Ingredients (NDI) for dietary supplements. CIRS Group provides an in-depth analysis of the key changes in the guidance to assist companies in conducting NDI compliance assessments and filing submissions for the U.S. market.

The FDA is modernizing its 30-year-old GRAS system by replacing voluntary notifications with a mandatory regime to close safety blind spots. Companies using human or animal food ingredients under GRAS provisions must notify the agency, though existing marketed ingredients benefit from a one-year simplified submission window and an 18-month overall compliance grace period.

CIRS Group Korea will take part in the 2026 Alternative Food Industry Expert Training Program (Cell-Cultured Food) run by the World Food Tech Council, delivering a session on the regulatory status and practice for novel food ingredients in overseas markets.

China NHC issued notifications regarding the acceptance of “three new foods”. The applications for 1 new food materials and 4 new food additives have been received.

On October 7, with comprehensive support from CIRS Group, Inner Mongolia Kingdomway Pharmaceutical Limited (hereinafter referred to as “Kingdomway”) officially received a “FDA Has No Questions Letter” from the U.S. Food and Drug Administration (FDA) for its fermentation-derived brazzein (GRAS Notice No. 001305). This milestone marks the successful completion of the FDA’s review of the company’s GRAS notice for the product.

China NHC issued notifications regarding the acceptance of “three new foods”. The applications for 3 new food materials (ingredients) and 4 new food additives have been received.

The EFSA Panel concluded that rebaudioside M produced via a new enzymatic process using genetically modified E. coli enzymes raises no safety concerns. Because no viable cells, DNA, or significant enzyme residues remain, and its physicochemical profile matches approved Reb M, previous toxicological safety data applies, supporting a distinct new food additive entry.

The EFSA Panel concluded that chemically synthesized cannabidiol (≥98% purity) in MCT oil is safe as a novel food supplement for adults over 25—excluding pregnant, breastfeeding, or medicated individuals—at a safe maximum intake of 2 mg per day.